5,6-Methylenedioxy-2-aminoindane (commonly known as MDAI) is an entactogen substance of the aminoindane chemical class that produces entactogenic effects when administered. Notably, this compound primarily produces the non-stimulating effects of prototypical entactogens like MDMA such as sedation, muscle relaxation, and tactile enhancement.
It acts as a putatively non-neurotoxic and highly selective serotonin releasing agent (SSRA) with neglible effects on dopamine and norepinephrine. This reportedly limits its potential at producing overtly invigorating, prosocial or euphoric effects.
MDAI has been marketed alongside research chemical entactogens like 5-MAPB, 5-APB, and 6-APB as a legal, grey-market alternative to MDMA.
MDAI, or 5,6-methylenedioxy-2-aminoindane, is a synthetic molecule of the aminoindane class with structural similarity to amphetamines.
Sedation – The biggest difference between MDAI and MDMA is that due to a comparative lack of dopamine reuptake inhibition.
Spontaneous physical sensations
Temperature regulation suppression
Temporary erectile dysfunction
The visual effects of MDAI only occur at higher doses and are reported to be only subtly psychedelic in nature. These generally include:
Visual acuity enhancement
MDAI is sold for research purposes only and is not be utilized for any other purposes.